Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Pharmacogenomics analysis using whole exome sequencing v1

View through CrossRef
For whole-exome sequencing, genomic DNA was extracted from peripheral blood cells and amplified with a 175-250 bp DNA fragment. The protein coding region of human genomic DNA was collected using an ion-exchange enzyme Exome Panel (Thermo Fisher Scientific, Waltham, Mass.). To load the DNA sample into the semiconductor chip, the library configuration was done by using the Ion Ampliseq Exome Library Kit Plus containing 57,742,646 bp (1.85% of the human genomic region) as described in the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA). The library was diluted to ~ 10 pM. We then combined the barcode library into sets of two barcodes. The exon-riched DNA libraries were sequenced using the ion Proton platform according to the manufacturer's instructions. (Thermo Fisher Scientific, Waltham, Mass.). The average depth of exome sequencing ranging from 80 to 120X was obtained and considered to be of sufficient depth to examine the exon for mutations. Raw reads were initially mapped to the human reference genome build (GRCh37) using the Torrent Mapping Alignment Program (TMAP). Genome Analysis Toolkit 2.8-1 and HaplotypeCaller [1] were used to call single base mutation types (SNV) and short insert / delete (INDEL), respectively. All variants were annotated by the Sorting Intolerant from Tolerant (SIFT) [2] algorithm using the SIFT database distributed by the J. Craig Venter Institute (http://sift.jcvi.org/). The SIFT human database that supports GRCh37 Ensembl release 63 (the latest version) was downloaded. After SIFT score annotation, we calculated gene deleteriousness score for each genes. The gene deleteriousness score (G) of a gene was defined as the geometric mean of the SIFT scores for all SIFT score annotated nonsynonymous coding variants of the gene to evaluate the overall impact of multiple deleterious variants on the gene [3]. Drug deleteriousness score (D) was calculated by the geometric mean of the G scores for all drug related pharmacokinetics/pharmacodynamics genes based on the knowlegde of DrugBank database (accessed September 4, 2015 at http://www.drugbank.ca/). References [1] McKenna AH, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research. 2010 Jul 19;gr.107524.110. [2] Kumar P, Henikoff S, Ng PC. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4:1073–81. [3] Lee KH, Baik SY, Lee SY, Park CH, Park PJ, Kim JH. Genome Sequence sequence Variability variability Predicts predicts Drug Precautions and Withdrawals from the Market. PLOoS ONE. 2016 30;11(9):e0162135.
Title: Pharmacogenomics analysis using whole exome sequencing v1
Description:
For whole-exome sequencing, genomic DNA was extracted from peripheral blood cells and amplified with a 175-250 bp DNA fragment.
The protein coding region of human genomic DNA was collected using an ion-exchange enzyme Exome Panel (Thermo Fisher Scientific, Waltham, Mass.
).
To load the DNA sample into the semiconductor chip, the library configuration was done by using the Ion Ampliseq Exome Library Kit Plus containing 57,742,646 bp (1.
85% of the human genomic region) as described in the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA).
The library was diluted to ~ 10 pM.
We then combined the barcode library into sets of two barcodes.
The exon-riched DNA libraries were sequenced using the ion Proton platform according to the manufacturer's instructions.
(Thermo Fisher Scientific, Waltham, Mass.
).
The average depth of exome sequencing ranging from 80 to 120X was obtained and considered to be of sufficient depth to examine the exon for mutations.
Raw reads were initially mapped to the human reference genome build (GRCh37) using the Torrent Mapping Alignment Program (TMAP).
Genome Analysis Toolkit 2.
8-1 and HaplotypeCaller [1] were used to call single base mutation types (SNV) and short insert / delete (INDEL), respectively.
All variants were annotated by the Sorting Intolerant from Tolerant (SIFT) [2] algorithm using the SIFT database distributed by the J.
Craig Venter Institute (http://sift.
jcvi.
org/).
The SIFT human database that supports GRCh37 Ensembl release 63 (the latest version) was downloaded.
After SIFT score annotation, we calculated gene deleteriousness score for each genes.
The gene deleteriousness score (G) of a gene was defined as the geometric mean of the SIFT scores for all SIFT score annotated nonsynonymous coding variants of the gene to evaluate the overall impact of multiple deleterious variants on the gene [3].
Drug deleteriousness score (D) was calculated by the geometric mean of the G scores for all drug related pharmacokinetics/pharmacodynamics genes based on the knowlegde of DrugBank database (accessed September 4, 2015 at http://www.
drugbank.
ca/).
References [1] McKenna AH, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al.
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.
Genome Research.
2010 Jul 19;gr.
107524.
110.
[2] Kumar P, Henikoff S, Ng PC.
Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm.
Nat Protoc.
2009;4:1073–81.
[3] Lee KH, Baik SY, Lee SY, Park CH, Park PJ, Kim JH.
Genome Sequence sequence Variability variability Predicts predicts Drug Precautions and Withdrawals from the Market.
PLOoS ONE.
2016 30;11(9):e0162135.

Related Results

Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Pharmacogenomics and the Concept of Personalized Medicine for the Management of Hypertension
Hypertension poses a significant global burden due to low adherence to antihypertensive medications. Hypertension treatment aims to bring blood pressure within physiological ranges...
Abstract 2094: Comparing exome with whole-genome next-generation sequencing in detecting somatic mutations
Abstract 2094: Comparing exome with whole-genome next-generation sequencing in detecting somatic mutations
Abstract Exome sequencing has been used as an efficient and cost-effective method of identifying somatic mutations in tumors. In order to evaluate the effectiveness ...
Evaluating the genetic diagnostic power of exome sequencing: Identifying missing data
Evaluating the genetic diagnostic power of exome sequencing: Identifying missing data
ABSTRACTA hurdle of exome sequencing is its limited capacity to represent the entire exome. To ascertain the diagnostic power of this approach we determined the extent of coverage ...
Clinical Pharmacogenomics
Clinical Pharmacogenomics
Pharmacogenomics is a tool for practitioners to provide precision pharmacotherapy using genomics. All providers are likely to encounter genomic data in practice with the expectatio...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...
Abstract 765: Hybridized-capture sequencing methods bias analysis of antigen presentation genes
Abstract 765: Hybridized-capture sequencing methods bias analysis of antigen presentation genes
Abstract Introduction: Tumor-immune dynamics are often interrogated using hybridized capture-based sequencing approaches which require the use of baits that target t...

Back to Top